| 臺大學術典藏 |
2021-02-23T08:26:32Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Yang S.-H. ;Kuo Y.-H. ;Tien Y.-W. ;Hsu C. ;Hsu C.-H. ;Sung-Hsin Kuo ;Cheng A.-L.; Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; SUNG-HSIN KUO; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:32Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Sung-Hsin Kuo ;Cheng A.-L. ;Lin C.-W. ;Hsu C.-H. ;Wu M.-S. ;Yeh K.-H. ;Tzeng Y.-S. ;Chen L.-T.; SUNG-HSIN KUO; Cheng A.-L.; Lin C.-W.; Hsu C.-H.; Wu M.-S.; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-23T08:26:28Z |
Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-�eb is associated with a poor prognosis of pancreatic cancer
|
Yang S.-H.;Hsu C.-H.;Lee J.-C.;Tien Y.-W.;Sung-Hsin Kuo;Cheng A.-L.; Yang S.-H.; Hsu C.-H.; Lee J.-C.; Tien Y.-W.; SUNG-HSIN KUO; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:21Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2021-02-04T02:30:20Z |
The preparation of cell-containing microbubble scaffolds to mimic alveoli structure as a 3D drug-screening system for lung cancer
|
Sun, Y.-J.;Hsu, C.-H.;Ling, T.-Y.;Liu, L.;Lin, T.-C.;Jakfar, S.;Young, I.-C.;Lin, F.-H.Feng-Huei Lin; Sun, Y.-J.; Hsu, C.-H.; Ling, T.-Y.; Liu, L.; Lin, T.-C.; Jakfar, S.; Young, I.-C.; Lin, F.-H.; FENG-HUEI LIN |
| 臺大學術典藏 |
2021-02-04T02:29:43Z |
Process integration of E-waste carbonization and High-gravity rotating packed bed for optimal gold recovery and the fine particles reduction
|
Huynh, G.-H.;Chen, T.-L.;Hsu, C.-H.;Chen, Y.-H.;Chiang, P.-C.; Huynh, G.-H.; Chen, T.-L.; Hsu, C.-H.; Chen, Y.-H.; Chiang, P.-C.; PEN-CHI CHIANG |
| 臺大學術典藏 |
2021-02-03T05:42:26Z |
Esophageal adenocarcinoma arising from Barrett's epithelium in Taiwan
|
CHIA-HUNG TU; Lee C.-T.; Perng D.-S.; Chang C.-C.; Hsu C.-H.; Lee Y.-C. |
| 臺大學術典藏 |
2021-02-02T08:29:56Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; BOR-RU LIN; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T05:45:47Z |
Esophageal adenocarcinoma arising from Barrett's epithelium in Taiwan
|
Tu C.-H.;Lee C.-T.;Perng D.-S.;Chang C.-C.;Hsu C.-H.;Yi-Chia Lee; Tu C.-H.; Lee C.-T.; Perng D.-S.; Chang C.-C.; Hsu C.-H.; YI-CHIA LEE |
| 臺大學術典藏 |
2021-02-02T02:22:37Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:21:42Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Kuo S.-H.; Cheng A.-L.; Lin C.-W.; Hsu C.-H.; MING-SHIANG WU; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Yeong-Shiau Pu;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y.; Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; YEONG-SHIAU PU; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Lin C.-C.;Hsu C.-H.;Chen J.;Tsai T.-C.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Chen J.; Tsai T.-C.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma
|
Hsu C.-H.;Chen J.;Wu C.-Y.;Cheng A.-L.;Yeong-Shiau Pu; Hsu C.-H.; Chen J.; Wu C.-Y.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:47:00Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Cheng A.-L.;Chen J.;Vogelzang N.J.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Cheng A.-L.; Chen J.; Vogelzang N.J.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:47:00Z |
Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study
|
Lin C.-C.;Hsu C.-H.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:59Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Cheng A.-L.;Vogelzang N.J.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Cheng A.-L.; Vogelzang N.J.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Tsai Y.-C.;Huang K.-H.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Lin C.-C.;Hsu C.-H.;Hour T.-C.;Cheng A.-L.;Huang C.-Y.;Huang K.-H.;Chen J.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Hour T.-C.; Cheng A.-L.; Huang C.-Y.; Huang K.-H.; Chen J.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Keng H.-Y.;Tsai Y.-C.;Huang K.-H.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:53Z |
Systemic therapy for metastatic urothelial carcinoma
|
Lin C.-C.; Hsu C.-H.; YEONG-SHIAU PU; Vogelzang N.J. |
| 臺大學術典藏 |
2021-02-02T00:46:51Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Lin C.-C.; YEONG-SHIAU PU; Hsu C.-H.; Keng H.-Y.; Cheng A.-L.; Yang C.-H. |
| 臺大學術典藏 |
2021-02-02T00:46:47Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; Tsai Y.-C.; Hsu F.-M.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:29Z |
Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells
|
Huang K.-H.; Kuo K.-L.; Ho I.-L.; Chang H.-C.; Chuang Y.-T.; Lin W.-C.; Lee P.-Y.; Chang S.-C.; Chiang C.-K.; YEONG-SHIAU PU; Chou C.-T.; Hsu C.-H.; Liu S.-H. |
| 臺大學術典藏 |
2021-02-02T00:46:21Z |
MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies
|
Kuo K.-L.;Ho I.-L.;Shi C.-S.;Wu J.-T.;Lin W.-C.;Tsai Y.-C.;Chang H.-C.;Chou C.-T.;Hsu C.-H.;Hsieh J.-T.;Chang S.-C.;Yeong-Shiau Pu;Huang K.-H.; Kuo K.-L.; Ho I.-L.; Shi C.-S.; Wu J.-T.; Lin W.-C.; Tsai Y.-C.; Chang H.-C.; Chou C.-T.; Hsu C.-H.; Hsieh J.-T.; Chang S.-C.; YEONG-SHIAU PU; Huang K.-H. |
| 臺大學術典藏 |
2021-02-02T00:46:17Z |
MLN4924 synergistically enhances cisplatin-induced cytotoxicity via jnk and bcl-xl pathways in human urothelial carcinoma
|
Ho I.-L.;Kuo K.-L.;Liu S.-H.-.;Chang H.-C.;Hsieh J.-T.;Wu J.-T.;Chiang C.-K.;Lin W.-C.;Tsai Y.-C.;Chou C.-T.;Hsu C.-H.;Yeong-Shiau Pu;Shi C.-S.;Huang K.-H.; Ho I.-L.; Kuo K.-L.; Liu S.-H.-.; Chang H.-C.; Hsieh J.-T.; Wu J.-T.; Chiang C.-K.; Lin W.-C.; Tsai Y.-C.; Chou C.-T.; Hsu C.-H.; YEONG-SHIAU PU; Shi C.-S.; Huang K.-H. |
| 臺大學術典藏 |
2021-02-02T00:46:08Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.;Cheng J.C.-H.;Huang C.-Y.;Tsai Y.-C.;Lin C.-C.;Hsu C.-H.;Cheng A.-L.;Yeong-Shiau Pu; Chiang Y.; Cheng J.C.-H.; Huang C.-Y.; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-01-28T03:15:20Z |
Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study
|
Shi C.-S.;Kuo K.-L.;Chen M.-S.;Po-Ming Chow;Liu S.-H.;Chang Y.-W.;Lin W.-C.;Liao S.-M.;Hsu C.-H.;Hsu F.-S.;Chang H.-C.;Huang K.-H.; Shi C.-S.; Kuo K.-L.; Chen M.-S.; PO-MING CHOW; Liu S.-H.; Chang Y.-W.; Lin W.-C.; Liao S.-M.; Hsu C.-H.; Hsu F.-S.; Chang H.-C.; Huang K.-H. |
| 臺大學術典藏 |
2021-01-28T03:15:20Z |
The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study
|
Kuo K.-L.;Liu S.-H.;Lin W.-C.;Po-Ming Chow;Chang Y.-W.;Yang S.-P.;Shi C.-S.;Hsu C.-H.;Liao S.-M.;Chang H.-C.;Huang K.-H.; Kuo K.-L.; Liu S.-H.; Lin W.-C.; PO-MING CHOW; Chang Y.-W.; Yang S.-P.; Shi C.-S.; Hsu C.-H.; Liao S.-M.; Chang H.-C.; Huang K.-H. |
| 臺大學術典藏 |
2021-01-28T02:03:54Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; KUO-HOW HUANG; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-01-28T02:03:54Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; KUO-HOW HUANG; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-01-28T02:03:53Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Lin C.-C.;Hsu C.-H.;Hour T.-C.;Cheng A.-L.;Huang C.-Y.;Kuo-How Huang;Chen J.;Pu Y.-S.; Lin C.-C.; Hsu C.-H.; Hour T.-C.; Cheng A.-L.; Huang C.-Y.; KUO-HOW HUANG; Chen J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-01-28T02:03:44Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; Tsai Y.-C.; Hsu F.-M.; KUO-HOW HUANG; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-01-28T02:03:27Z |
Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells
|
Kuo-How Huang;Kuo K.-L.;Ho I.-L.;Chang H.-C.;Chuang Y.-T.;Lin W.-C.;Lee P.-Y.;Chang S.-C.;Chiang C.-K.;Pu Y.-S.;Chou C.-T.;Hsu C.-H.;Liu S.-H.; KUO-HOW HUANG; Kuo K.-L.; Ho I.-L.; Chang H.-C.; Chuang Y.-T.; Lin W.-C.; Lee P.-Y.; Chang S.-C.; Chiang C.-K.; Pu Y.-S.; Chou C.-T.; Hsu C.-H.; Liu S.-H. |
| 臺大學術典藏 |
2021-01-28T02:03:22Z |
MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies
|
Kuo K.-L.;Ho I.-L.;Shi C.-S.;Wu J.-T.;Lin W.-C.;Tsai Y.-C.;Chang H.-C.;Chou C.-T.;Hsu C.-H.;Hsieh J.-T.;Chang S.-C.;Pu Y.-S.;Kuo-How Huang; Kuo K.-L.; Ho I.-L.; Shi C.-S.; Wu J.-T.; Lin W.-C.; Tsai Y.-C.; Chang H.-C.; Chou C.-T.; Hsu C.-H.; Hsieh J.-T.; Chang S.-C.; Pu Y.-S.; KUO-HOW HUANG |
| 臺大學術典藏 |
2021-01-28T02:03:18Z |
MLN4924 synergistically enhances cisplatin-induced cytotoxicity via jnk and bcl-xl pathways in human urothelial carcinoma
|
Ho I.-L.;Kuo K.-L.;Liu S.-H.-.;Chang H.-C.;Hsieh J.-T.;Wu J.-T.;Chiang C.-K.;Lin W.-C.;Tsai Y.-C.;Chou C.-T.;Hsu C.-H.;Pu Y.-S.;Shi C.-S.;Kuo-How Huang; Ho I.-L.; Kuo K.-L.; Liu S.-H.-.; Chang H.-C.; Hsieh J.-T.; Wu J.-T.; Chiang C.-K.; Lin W.-C.; Tsai Y.-C.; Chou C.-T.; Hsu C.-H.; Pu Y.-S.; Shi C.-S.; KUO-HOW HUANG |
| 臺大學術典藏 |
2021-01-28T02:02:58Z |
Epigallocatechin Gallate Attenuates Partial Bladder Outlet Obstruction-induced Bladder Injury via Suppression of Endoplasmic Reticulum Stress-related Apoptosis - In Vivo Study
|
Hsieh J.-T.; Kuo K.-L.; Liu S.-H.; Shi C.-S.; Chang H.-C.; Lin W.-C.; Chou C.-T.; Hsu C.-H.; Liao S.-M.; Wang Z.-H.; Li C.-C.; KUO-HOW HUANG |
| 臺大學術典藏 |
2021-01-28T02:02:45Z |
Trifluoperazine, an antipsychotic drug, effectively reduces drug resistance in cisplatin-resistant urothelial carcinoma cells via suppressing bcl-xl: An in vitro and in vivo study
|
Kuo K.-L.;Liu S.-H.;Lin W.-C.;Hsu F.-S.;Chow P.-M.;Chang Y.-W.;Yang S.-P.;Shi C.-S.;Hsu C.-H.;Liao S.-M.;Chang H.-C.;Kuo-How Huang; Kuo K.-L.; Liu S.-H.; Lin W.-C.; Hsu F.-S.; Chow P.-M.; Chang Y.-W.; Yang S.-P.; Shi C.-S.; Hsu C.-H.; Liao S.-M.; Chang H.-C.; KUO-HOW HUANG |
| 臺大學術典藏 |
2021-01-28T02:02:44Z |
The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study
|
Kuo K.-L.;Liu S.-H.;Lin W.-C.;Chow P.-M.;Chang Y.-W.;Yang S.-P.;Shi C.-S.;Hsu C.-H.;Liao S.-M.;Chang H.-C.;Kuo-How Huang; Kuo K.-L.; Liu S.-H.; Lin W.-C.; Chow P.-M.; Chang Y.-W.; Yang S.-P.; Shi C.-S.; Hsu C.-H.; Liao S.-M.; Chang H.-C.; KUO-HOW HUANG |
| 臺大學術典藏 |
2021-01-28T02:02:43Z |
Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study
|
Shi C.-S.;Kuo K.-L.;Chen M.-S.;Chow P.-M.;Liu S.-H.;Chang Y.-W.;Lin W.-C.;Liao S.-M.;Hsu C.-H.;Hsu F.-S.;Chang H.-C.;Kuo-How Huang; Shi C.-S.; Kuo K.-L.; Chen M.-S.; Chow P.-M.; Liu S.-H.; Chang Y.-W.; Lin W.-C.; Liao S.-M.; Hsu C.-H.; Hsu F.-S.; Chang H.-C.; KUO-HOW HUANG |
| 臺大學術典藏 |
2021-01-28T01:07:01Z |
Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers
|
Hsu C.-H.;Kun-Huei Yeh;Chen L.-T.;Liu J.M.;Jan C.-M.;Lin J.-T.;Chen Y.-C.;Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Chen L.-T.; Liu J.M.; Jan C.-M.; Lin J.-T.; Chen Y.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:07:00Z |
Thymic carcinoma with autoimmune syndrome: Successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin
|
Hsu C.-H.;Kun-Huei Yeh;Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:07:00Z |
A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers
|
Kun-Huei Yeh;Cheng A.-L.;Lin M.-T.;Hong R.-L.;Hsu C.-H.;Lin J.-F.;Chang K.-J.;Lee P.-H.;Chen Y.-C.; KUN-HUEI YEH; Cheng A.-L.; Lin M.-T.; Hong R.-L.; Hsu C.-H.; Lin J.-F.; Chang K.-J.; Lee P.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2021-01-28T01:06:55Z |
Concurrent chemoradiotherapy for locally advanced esophageal cancer - A pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil
|
Hsu C.-H.;Kun-Huei Yeh;Lui L.T.;Lee Y.-C.;Bu C.-F.;Wang H.-P.;Lin J.-T.;Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Lui L.T.; Lee Y.-C.; Bu C.-F.; Wang H.-P.; Lin J.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:54Z |
Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil
|
Kun-Huei Yeh;Yeh S.-H.;Hsu C.-H.;Wang T.-M.;Ma I.-F.;Cheng A.-L.; KUN-HUEI YEH; Yeh S.-H.; Hsu C.-H.; Wang T.-M.; Ma I.-F.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:53Z |
P53 Overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection
|
Liang J.-T.;Huang K.-C.;Cheng Y.-M.;Hsu H.-C.;Cheng A.-L.;Hsu C.-H.;Kun-Huei Yeh;Wang S.-M.;Chang K.-J.; Liang J.-T.; Huang K.-C.; Cheng Y.-M.; Hsu H.-C.; Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Wang S.-M.; Chang K.-J. |
| 臺大學術典藏 |
2021-01-28T01:06:53Z |
Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma
|
Huang C.-L.;Lin Z.-Z.;Su I.-J.;Chao T.-Y.;Tien H.-F.;Chang M.-C.;Huang M.-C.;Kao W.-Y.;Tang J.-L.;Kun-Huei Yeh;Wang C.-H.;Hsu C.-H.;Liu M.-Y.;Cheng A.-L.; Huang C.-L.; Lin Z.-Z.; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; KUN-HUEI YEH; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:52Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Kun-Huei Yeh; Hsu C.-H.; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:52Z |
High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection
|
Liang J.-T.;Huang K.-C.;Lai H.-S.;Lee P.-H.;Cheng Y.-M.;Hsu H.-C.;Cheng A.-L.;Hsu C.-H.;Kun-Huei Yeh;Wang S.-M.;Tang C.;Chang K.-J.; Liang J.-T.; Huang K.-C.; Lai H.-S.; Lee P.-H.; Cheng Y.-M.; Hsu H.-C.; Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Wang S.-M.; Tang C.; Chang K.-J. |
| 臺大學術典藏 |
2021-01-28T01:06:50Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Kun-Huei Yeh;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L. |
